Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer.

PURPOSE The growth arrest and DNA damage-inducible 45 gene (GADD45a) is one of the downstream mediators of the p53 gene that stimulates DNA excision repair. The present study was designed to assess the clinicopathological significance of GADD45a and p53 in resectable invasive ductal carcinomas (IDCs) of the pancreas. EXPERIMENTAL DESIGN This study included 72 pancreatic IDC patients who received surgery between 1982 and 2001. Point mutations in exons 1 and 4 of GADD45a and the expression of the GADD45a gene product (Gadd45) and p53 protein were analyzed by direct DNA sequencing and immunohistochemistry. RESULTS Point mutations were found in exon 4 of GADD45a in eight cases (13.6%). Gadd45 and p53 were expressed in 54.2% (39 of 72) and 47.2% (34 of 72) of the patients. The expression of Gadd45 did not necessarily correlate with that of p53. However, Gadd45 expression correlated significantly with the grade of the pT factor of the tumors. Coexpression analysis of Gadd45 and p53 indicated that in patients with p53(+) IDC, the Gadd45(+) group had a significantly lower survival rate than the Gadd45(-) group. Furthermore, Gadd45 expression had no effect on the efficacy of the adjuvant chemotherapy. Multivariate analysis indicated that pTNM (tumor-node-metastasis) stage, grade, and adjuvant chemotherapy were significant variables for survival. Furthermore, in the p53(-) group, there were no significant variables. In contrast, in the p53(+) group, pTNM stage, histological grade, and Gadd45 expression were significant variables. CONCLUSIONS The frequency of GADD45a mutation is appreciable in human pancreatic IDC, and the expression of Gadd45, combined with that of p53, significantly affects the survival of patients with resectable IDCs of the pancreas.

[1]  W. El-Deiry,et al.  Comparative gene expression profiling in response to p53 in a human lung cancer cell line. , 1999, Biochemical and biophysical research communications.

[2]  K. Yamasawa,et al.  Apoptosis and Expression of Bcl-2 and Bax Proteins in Invasive Ductal Carcinoma of the Pancreas , 2001, Pancreas.

[3]  H. Hayatsu,et al.  Evaluation of blue-chitin column, blue-rayon hanging, and XAD-resin column techniques for concentrating mutagens from two Japanese rivers. , 1996, Mutation research.

[4]  William F. Morgan,et al.  Genomic instability in Gadd45a-deficient mice , 1999, Nature Genetics.

[5]  T. Colby,et al.  Long‐Term Survival After Resection for Ductal Adenocarcinoma of the Pancreas Is It Really Improving? , 1995, Annals of surgery.

[6]  T. Myers,et al.  An informatics approach identifying markers of chemosensitivity in human cancer cell lines. , 2000, Cancer research.

[7]  K. Kohn,et al.  The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth , 1994, Molecular and cellular biology.

[8]  S. Sumi,et al.  p53 protein expression as prognostic factor in human pancreatic cancer. , 1997, Anticancer research.

[9]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[10]  A. Fornace,et al.  Induction by ionizing radiation of the gadd45 gene in cultured human cells: lack of mediation by protein kinase C. , 1991, Molecular and cellular biology.

[11]  C. Harris,et al.  GADD45 induction of a G2/M cell cycle checkpoint. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Y. Nio,et al.  Ki-ras point mutation and p53 expression in human pancreatic cancer: a comparative study among Chinese, Japanese, and Western patients. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[13]  Y. Nio,et al.  Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. , 1997, Anticancer research.

[14]  F. Salvi,et al.  Radiation-induced gadd45 expression correlates with clinical response to radiotherapy of cervical carcinoma. , 2000, International journal of radiation oncology, biology, physics.

[15]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[16]  S. Friend,et al.  Characterization of human Gadd45, a p53-regulated protein. , 1994, The Journal of biological chemistry.

[17]  J. Marx.  New link found between p53 and DNA repair. , 1994, Science.

[18]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[19]  S. Goodman,et al.  Overexpression of p53 protein in adenocarcinoma of the pancreas. , 1994, American journal of clinical pathology.

[20]  M. Hollstein,et al.  Clinical implications of the p53 tumor-suppressor gene. , 1993, The New England journal of medicine.

[21]  A. Fornace,et al.  Analysis of the mammalian gadd45 gene and its response to DNA damage. , 1993, The Journal of biological chemistry.

[22]  D. Ayers,et al.  Characterization of the GADD45 response to ionizing radiation in WI-L2-NS cells, a p53 mutant cell line. , 1996, Mutation research.

[23]  A. Murray,et al.  Creative blocks: cell-cycle checkpoints and feedback controls , 1992, Nature.

[24]  D. Lane,et al.  Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells , 1991, Nature.

[25]  S. Sumi,et al.  Correlation Between TGF-β1 and p21 (WAF1/CIP1) Expression and Prognosis in Resectable Invasive Ductal Carcinoma of the Pancreas , 2001, Pancreas.

[26]  P. O'Connor,et al.  Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. , 1994, Science.

[27]  S. Friend,et al.  The importance of p53 gene alterations in human cancer: is there more than circumstantial evidence? , 1993, Journal of the National Cancer Institute.

[28]  S. Syrjänen,et al.  p53 protein expression in breast cancer as related to histopathological characteristics and prognosis , 1993, International journal of cancer.

[29]  Stephen J. Elledge,et al.  Cell Cycle Checkpoints: Preventing an Identity Crisis , 1996, Science.

[30]  M. Kastan,et al.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. Campomenosi,et al.  Gadd45 mutations are uncommon in human tumour cell lines , 2000, Cell proliferation.

[32]  G. Jayson,et al.  p53 and related proteins in epithelial ovarian cancer. , 2000, European journal of cancer.

[33]  A. Fornace,et al.  Response to adversity: molecular control of gene activation following genotoxic stress. , 1991, The New biologist.

[34]  T. Visakorpi,et al.  Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. , 1992, Journal of the National Cancer Institute.

[35]  B. Vogelstein,et al.  Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. , 1985, Biochemical and biophysical research communications.

[36]  A. Piccoli,et al.  Survival after resection for ductal adenocarcinoma of the pancreas , 1996, The British journal of surgery.

[37]  J. Bartek,et al.  An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. , 1992, Journal of immunological methods.

[38]  A. Fornace,et al.  DNA damage-inducible transcripts in mammalian cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Y. Nio,et al.  Comparative significance of p53 and WAF/1-p21 expression on the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma of the pancreas. , 1999, Pancreas.

[40]  R. Muschel,et al.  The molecular basis for cell cycle delays following ionizing radiation: a review. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[41]  W. El-Deiry,et al.  Regulation of p53 downstream genes. , 1998, Seminars in cancer biology.

[42]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[43]  H. Friess,et al.  p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. , 1993, Cancer letters.

[44]  Y. Nio,et al.  Clinicopathological significance of Ki-ras point mutation and p21 expression in benign and malignant exocrine tumors of the human pancreas , 1996 .

[45]  K Nasmyth,et al.  Viewpoint: Putting the Cell Cycle in Order , 1996, Science.